Table 2 Outcomes and complications
Variable | Vancomycin & Cefazolin (n = 1,437) | Cefazolin (n = 1,470) | P-value | ||
|---|---|---|---|---|---|
n | % | n | % | ||
30-day Complications | |||||
Emergency | 60 | 4.2% | 80 | 5.4% | 0.131 |
Inpatient Readmission | 53 | 3.7% | 97 | 6.6% | < 0.001 |
90-day Complications | |||||
PJI | 5 | 0.3% | 8 | 0.5% | 0.394 |
SSI | 3 | 0.2% | 8 | 0.5% | 0.172 |
1-year Complications | |||||
PJI | 12 | 0.8% | 17 | 1.2% | 0.279 |
SSI | 3 | 0.2% | 9 | 0.6% | 0.089 |
PJI Infecting Organism | |||||
MRSA | 1 | 0.1% | 2 | 0.1% | 0.999 |
MSSA | 1 | 0.1% | 4 | 0.3% | 0.229 |
Serratia marcescens | 1 | 0.1% | 0 | 0.0% | 0.225 |
Streptococcus agalactiae | 2 | 0.1% | 0 | 0.0% | 0.225 |
Streptococcus viridans | 0 | 0.0% | 1 | 0.1% | 0.231 |
Polymicrobial | 0 | 0.0% | 2 | 0.1% | 0.231 |
No growth | 7 | 0.5% | 8 | 0.5% | 0.999 |
SSI Infecting Organism | |||||
Corynebacterium | 0 | 0.0% | 1 | 0.1% | 0.231 |
MSSA | 0 | 0.0% | 3 | 0.2% | 0.089 |
Peptococcus species | 0 | 0.0% | 1 | 0.1% | 0.231 |
Polymicrobial | 2 | 0.1% | 2 | 0.1% | 0.999 |
No growth | 1 | 0.1% | 2 | 0.1% | 0.999 |